Anxiety medications might be tested on people not anxious enough
DUNEDIN: Anxiety medications might be tested on people not anxious enough, researchers say.
University of Otago psychiatry experts have expressed concern that some anxiety medications might appear ineffective because they are not being tested on appropriate patients.
Researchers went to find out why there was a variation in results among placebo-controlled trials of benzodiazepines.
Benzodiazepines are drugs, like diazepam (first marketed as Valium), used to treat severe anxiety and sleep problems.
Dunedin School of Medicine senior lecturer and consultant psychiatrist said a review of randomised controlled trials with benzodiazepines used in generalised anxiety disorder showed most of the variation related to the severity of anxiety before treatment.
Researchers also found the length of the trial made a difference, with longer trials having less effect.
This finding was expected given that benzodiazepines were medications where people developed tolerance over time.
While benzodiazepines were still widely used for treatment, Gale said the results had a concerning implication.
“We may be using the wrong population to test medications. This community-recruited group, particularly in psychiatry, may be giving us a false result that useful medications are no better than placebo.”
Older trials generally involved people with severe anxiety, including some who were hospitalised, while many newer trials involved recruiting study participants from the community by newspaper advertisements and social media.
“This newer population may not be the same as the patients we see clinically, in that their anxiety may be much less severe. Placebos appear to work as well as benzodiazepines in this less severely affected patient group,” Gale said.
“However, in the more severe group, benzodiazepines are superior.”
To ensure appropriate information about the use of benzodiazepines, researchers advocated recruiting people for testing who are either receiving treatment or in need of treatment for psychiatry or pain-related conditions.
It may also mean a large number of trials, particularly in anxiety disorders needed to be re-analysed to take into account the level of severity of anxiety, he said.






